DNA — Ginkgo Bioworks Holdings, Inc.

Is DNA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $8.32. The rating moved from Oversold to Strong Oversold on November 15, 2026.

See all oversold Healthcare stocks →

AI analysis

Ginkgo Bioworks Holdings, Inc. (DNA) runs a differentiated synthetic-biology platform with validated commercial partnerships and a path to higher-margin service streams as automation and program scale improve. The company benefits from a large addressable market in biotech and industrial biology, but near-term fundamentals are constrained by cash burn, lengthy commercialization timelines and execution risk. Market conditions remain mildly supportive for selective growth names, but limited public sentiment and funding sensitivity mean shares are likely to trade with volatility until clearer revenue cadence and margin expansion are demonstrated.

Key factors

  • Ginkgo Bioworks Holdings, Inc. (DNA) operates a scalable organism-engineering platform and biofoundry model that drives service and collaboration revenue from pharma, agriculture and industrial customers.
  • Diversified commercial engagements and partnerships with large biopharma and industrial customers provide recurring/project revenue and validation of platform capabilities.
  • Addressable market growth for synthetic biology and biologics development supports long-term demand for engineering services, cell lines and associated analytics.
  • Path to margin improvement via automation, software-enabled workflows and higher-margin long-term programs as platform utilization increases.
  • Recent market tone shows selective support for growth/biotech names, which could help share-price stability amid earnings and sector flows.
  • Limited social/research signals and no recent EDGAR comparisons available increase reliance on company disclosures and partnership announcements for near-term catalysts.

Risks

  • High cash burn and funding needs that may lead to equity dilution or costly financing if revenue ramp is slower than expected.
  • Long sales cycles and execution risk on converting partnerships into sustained, high-margin recurring revenue.
  • Technical and operational scale-up challenges when moving programs from R&D to commercial production.
  • Competitive pressure from other synthetic-biology platforms, contract research organizations and vertically integrated incumbents.
  • Regulatory uncertainty for engineered organisms and downstream product approvals that could lengthen timelines.
  • Customer concentration or reliance on a limited set of large partners could create revenue volatility if contracts lapse or terms change.
  • Macro/market volatility and sector rotation away from growth names could pressure valuation despite fundamental progress.

See today's live rating, score and targets

Members see the live hourly rating for DNA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.